Bay Street News, March, 2024

– Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) […]

DEFIANCE, Ohio, March 29, 2024 (GLOBE NEWSWIRE) — SB Financial Group, Inc. (NASDAQ: SBFG), a diversified financial services company providing […]

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 […]

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company […]

FORT LAUDERDALE, Fla., March 29, 2024 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi”), owner of one of […]

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target […]

— Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 —— Exploring opportunities […]

ZEELAND, Mich., March 29, 2024 (GLOBE NEWSWIRE) — Gentex Corporation (NASDAQ: GNTX), the Zeeland, Michigan-based supplier of digital vision, connected […]

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results […]

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) — Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose […]